Question 1

Am I eligible for this trial based on my specific cancer stage and type?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential benefits and risks of using Ensartinib before my surgery?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

Question 4

What kind of monitoring will I need during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to come in for visits and tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I do if I experience side effects during the treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer clinical trial (NCT05380024). Contact the study team or your healthcare provider for specific answers.

What this study is about